SEC Filing Analysis: Gilead Sciences, Inc. (GILD)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Vanguard Group has reorganized its reporting structure, resulting in the parent entity reporting 0 direct beneficial ownership while subsidiaries will report separately.
• Market Impact: Neutral - This is an administrative change, not a liquidation of holdings.

Company Information

Field	Value
Company	Gilead Sciences, Inc.
Ticker Symbol	GILD
CIK	0000882095
Industry	Biological Products

Insider Information

Field	Value
Name	The Vanguard Group
CIK	0000102909
Relationship	Institutional Investor

Transaction Details

Field	Value
Form Type	SCHEDULE 13G/A
Transaction Date	2026-03-13
Shares Owned After	0
Ownership %	0%

Financial Impact Assessment

Transaction Materiality

Metric	Value
Market Cap	$170.34 Billion
Shares Outstanding	1.24 Billion
Materiality Assessment	Low (Administrative Event)

Impact Evaluation

• Market Cap Context: While Vanguard is a major holder, this specific filing represents a change in reporting methodology, not a change in investment thesis.
• Transaction Significance: The filing explicitly states: "The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries." This is a compliance update.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: No shares were sold into the open market based on this filing. The change is purely legal/administrative regarding how Vanguard aggregates subsidiary holdings.

Volume & Sentiment

• Expected Volume Impact: None.
• Sentiment Indicator: Neutral.

Additional Context

Transaction Notes

• Special Circumstances: The filing cites SEC Release No. 34-39538 (January 12, 1998), allowing subsidiaries to report beneficial ownership separately from the parent holding company. Investors should expect subsequent filings from Vanguard subsidiaries (e.g., Vanguard Fiduciary Trust Co, Vanguard Investments Australia, etc.) showing their respective stakes.